References
- Frey SP, Hardes J, Ahrens H, Winkelmann W, Gosheger G. Total tibia replacement using an allograft (in a patient with adamantinoma). Case report and review of literature. J Cancer Res Clin Oncol 2008;134:427–31.
- Qureshi AA, Shott S, Mallin BA, Gitelis S. Current trends in the management of adamantinoma of long bones. An international study. J Bone Joint Surg Am 2000;82-A:1122–31.
- Hazelbag HM, Taminiau AH, Fleuren GJ, Hogendoorn PC. Adamantinoma of the long bones. A clinicopathological study of thirty-two patients with emphasis on histological subtype, precursor lesion, and biological behavior. J Bone Joint Surg Am 1994;76:1482–99.
- Lokich J. Metastatic adamantinoma of bone to lung. A case report of the natural history and the use of chemotherapy and radiation therapy. Am J Clin Oncol 1994;17:157–9.
- Dudek AZ, Murthaiah PK, Franklin M, Truskinovsky AM. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor. Acta Oncol 2010;49:101–4.
- Van Der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–86.
- Motzer R, Hutson TE, Reeves J, Hawkins R, Guo J, Nathan P, et al. Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): Results of the COMPARZ trial. 37th ESMO Congress; 2012 Sep 28 – Oct 2; Vienna, Austria.